In case anybody missed it, Afamelanotide/Scenesse (equivalent of MT-1 in an implant form) has been approved in Europe for treatment of a rare genetic disease of people who are very sensitive to sunlight. It has been approved for several years in Switzerland and Italy already.
Basically, this means it will almost certainly be approved by the FDA, maybe early next year. Also, it's a very good sign that the use for Vitiligo will be approved once the trials are complete. Once that happens, we can probably assume that this will be available off-label then. For EPP it's likely to be more tightly regulated since it's a very rare disease.
Reply With Quote